Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
{{output}}
Background: Ipilimumab is the first cytotoxic T lymphocyte protein-4 (CTLA-4) inhibitor approved in the United States. However, there is insufficient data on the safety of this drug in elderly patients. This study aimed to identi... ...
